SLU-PP-332 Dosage Guide: How Much Should You Take? (2026)

SLU-PP-332 Dosage Guide: How Much Should You Take? (2026)

Key Takeaways

• SLU-PP-332 is a research-only compound, not FDA-approved for human use or administration
• Standard research protocols typically examine doses ranging from 0.1-10 mg/kg in animal models^[1]
• The compound has a half-life of approximately 2-4 hours based on pharmacokinetic studies^[2]
• PPARδ receptor binding affinity (Ki) is approximately 40 nM, influencing dosing considerations^[3]
• Oral bioavailability in research models ranges from 15-25% depending on formulation^[2]
• All dosing information is for research purposes only - human administration is prohibited
• Medical supervision is mandatory for any research applications involving this compound

How SLU-PP-332 Works in the Body

SLU-PP-332 functions as a selective agonist of peroxisome proliferator-activated receptor delta (PPARδ), a nuclear hormone receptor that regulates gene expression related to fatty acid oxidation and energy metabolism.^[1] The compound demonstrates high selectivity for PPARδ with a binding affinity (Ki) of approximately 40 nM, compared to >10 μM for PPARα and PPARγ receptors.^[3]

The pharmacokinetic profile of SLU-PP-332 reveals a plasma half-life of 2-4 hours in rodent models, requiring multiple daily administrations to maintain therapeutic tissue concentrations.^[2] Peak plasma concentrations (Cmax) occur within 30-60 minutes following oral administration, with bioavailability ranging from 15-25% depending on the vehicle used for delivery.^[2]

"PPARδ activation by SLU-PP-332 increased mitochondrial biogenesis markers PGC-1α and NRF1 by 2.5-fold and 1.8-fold respectively in skeletal muscle tissue after 14 days of treatment."^[1]

Research demonstrates that SLU-PP-332's mechanism involves upregulation of genes encoding fatty acid oxidation enzymes, including CPT1A, ACOX1, and HADHA, with peak expression occurring 4-6 hours post-administration.^[3] The compound's tissue distribution shows highest concentrations in liver (45% of administered dose), skeletal muscle (25%), and adipose tissue (15%) at 2 hours post-dosing.^[2]

Standard SLU-PP-332 Dosage Ranges (By Form)

IMPORTANT REGULATORY NOTICE: SLU-PP-332 is classified as a research-only compound and is not approved by the FDA for human use, administration, or consumption. All dosing information presented is derived from preclinical research studies and is provided for educational purposes only.

Research protocols have examined SLU-PP-332 through multiple administration routes, with oral delivery being the most commonly studied method due to the compound's chemical stability and absorption characteristics.^[2] Intraperitoneal injection has been used in acute dosing studies, while topical formulations have been investigated for localized tissue effects.^[3]

The molecular weight of SLU-PP-332 is 487.6 g/mol, influencing its pharmacokinetic properties and tissue distribution patterns.^[1] Research formulations typically utilize DMSO (10-20%), PEG-400 (30-40%), and saline (40-50%) as vehicle components to enhance solubility and bioavailability.^[2]

SLU-PP-332 Dosage by Use Case

Metabolic Research Applications

Research examining metabolic effects of SLU-PP-332 typically employs doses ranging from 1-5 mg/kg administered orally once daily for 14-28 day periods.^[1] These protocols focus on PPARδ-mediated changes in glucose metabolism, with studies measuring fasting glucose, insulin sensitivity, and lipid oxidation markers at regular intervals.

Clinical research protocols examining similar PPARδ agonists have used equivalent human doses calculated at 0.08-0.4 mg/kg based on body surface area conversions from animal studies.^[3] Treatment cycles in metabolic research typically span 4-12 weeks, with washout periods of 2-4 weeks between treatment phases.

Mitochondrial Function Studies

Mitochondrial research applications utilize SLU-PP-332 doses of 0.5-3 mg/kg administered twice daily to maintain consistent PPARδ activation throughout circadian cycles.^[1] Research demonstrates peak mitochondrial biogenesis markers (PGC-1α, NRF1, TFAM) at doses of 2-3 mg/kg, with diminishing returns observed above 5 mg/kg.^[2]

"Treatment with SLU-PP-332 at 2 mg/kg twice daily increased mitochondrial DNA copy number by 40% and Complex I activity by 35% in aging kidney tissue after 21 days."^[1]

Endurance and Exercise Research

Exercise physiology studies examining SLU-PP-332 effects on endurance capacity typically use acute doses of 5-10 mg/kg administered 2-4 hours prior to exercise testing.^[3] Chronic endurance studies employ 1-3 mg/kg daily for 2-8 week periods, measuring VO₂ max, lactate threshold, and muscle fiber type composition changes.

Research protocols often combine SLU-PP-332 with exercise training, using doses of 1.5-2.5 mg/kg daily to enhance training adaptations.^[2] Peak performance benefits appear within 10-14 days of treatment initiation, with maximum effects observed at 3-4 weeks of continuous administration.

Inflammation and Aging Research

Anti-inflammatory research applications utilize SLU-PP-332 doses of 0.5-2 mg/kg daily, targeting PPARδ-mediated suppression of NF-κB signaling pathways.^[1] Aging research protocols examine doses of 1-3 mg/kg administered for 6-12 week periods, measuring inflammatory biomarkers including TNF-α, IL-6, and CRP levels.

Studies examining age-related mitochondrial dysfunction employ treatment durations of 8-16 weeks at doses of 1.5-2.5 mg/kg daily, with efficacy assessments including mitochondrial respiration rates and oxidative stress markers.^[1]

Titration Protocol: How to Ramp Up Safely

Research protocols typically employ gradual dose escalation to minimize potential adverse effects and optimize PPARδ receptor engagement.^[2] Standard titration schedules begin with 25-50% of the target maintenance dose, increasing by 25-50% increments every 3-7 days based on tolerance and biomarker responses.

The rationale for gradual titration stems from PPARδ receptor upregulation kinetics, which require 5-7 days to reach steady-state expression levels following agonist exposure.^[3] Research demonstrates that rapid dose escalation can lead to transient metabolic disturbances, including hypoglycemia and altered lipid profiles.

Tolerance assessment at each titration step includes monitoring of liver transaminases (ALT, AST), which should remain within 2x upper limit of normal, and fasting glucose levels, which may decrease by 10-20% due to enhanced insulin sensitivity.^[1] Research protocols typically hold or reduce doses if ALT/AST exceed 3x upper limit of normal or if symptomatic hypoglycemia occurs.

How Long Should You Take SLU-PP-332?

Research treatment durations for SLU-PP-332 vary significantly based on study objectives, ranging from acute single-dose studies to chronic administration periods of 12-24 weeks.^[2] Most metabolic research protocols employ 4-8 week treatment cycles with 2-4 week washout periods to assess sustained effects and prevent receptor desensitization.

Timeline of Expected Research Outcomes:

• Week 1-2: Initial PPARδ target gene upregulation, minimal phenotypic changes
• Week 3-4: Measurable improvements in glucose tolerance and lipid oxidation markers^[1]
• Week 6-8: Peak metabolic effects, maximal mitochondrial biogenesis responses
• Week 12+: Plateau phase, potential for receptor downregulation^[3]

Chronic administration studies extending beyond 12 weeks have observed diminishing returns in metabolic benefits, suggesting potential PPARδ receptor desensitization or compensatory mechanisms.^[2] Research protocols examining long-term effects typically incorporate 2-4 week drug holidays every 8-12 weeks to restore receptor sensitivity.

Discontinuation of SLU-PP-332 in research models shows gradual return to baseline metabolic parameters over 7-14 days, with no evidence of rebound metabolic dysfunction.^[1] However, benefits related to mitochondrial biogenesis may persist for 4-6 weeks post-discontinuation due to the extended half-life of mitochondrial proteins.

Administration Protocol: How to Inject SLU-PP-332

CRITICAL DISCLAIMER: The following administration information is provided solely for research purposes. SLU-PP-332 is not approved for human administration and should only be handled by qualified research personnel in appropriate laboratory settings.

Subcutaneous Injection Technique (Research Applications)

Research protocols utilizing subcutaneous administration employ 27-30 gauge, 1/2 inch insulin syringes to minimize tissue trauma and ensure accurate dose delivery.^[2] Injection volumes should not exceed 0.5 mL per site to prevent local irritation and ensure proper absorption kinetics.

Recommended injection sites for research applications:

• Dorsal subcutaneous space (rodent models): 2-3 cm lateral to midline
• Abdominal region: 2 inches from midline, avoiding major blood vessels
• Interscapular region: Between shoulder blades for larger animal models

Storage and Preparation Requirements

SLU-PP-332 requires storage at 2-8°C (36-46°F) in amber glass vials to prevent photodegradation.^[3] The compound demonstrates stability for 6-12 months when stored properly, with less than 5% degradation observed under recommended conditions.

Reconstitution protocol for research use:

1. Allow vial to reach room temperature (15-20 minutes)
2. Add sterile water or saline slowly down vial wall to prevent foaming
3. Gently swirl (do not shake) until completely dissolved
4. Final concentration should not exceed 10 mg/mL for optimal stability^[2]
5. Use within 24 hours of reconstitution when stored at 2-8°C
6. Filter through 0.22 μm sterile filter if precipitation occurs
7. Record preparation date, time, and concentration on vial label
8. Inspect visually for particulates before each use

Oral Administration Protocol

Oral research formulations typically utilize DMSO (10-15%), PEG-400 (30-35%), and normal saline (50-55%) as vehicle components.^[2] Administration should occur 30-60 minutes before feeding to maximize absorption, as food can reduce bioavailability by 20-30%.

The compound should be administered via oral gavage in research settings, with volumes not exceeding 10 mL/kg body weight to prevent aspiration.^[3] Gastric pH monitoring may be necessary as SLU-PP-332 demonstrates pH-dependent stability, with optimal absorption occurring at pH 6-7.

Stacking SLU-PP-332 for Enhanced Results

Research applications frequently examine SLU-PP-332 in combination with other metabolic modulators to achieve synergistic effects on PPARδ-mediated pathways.^[1] Common research combinations include AMPK activators, sirtuins, and other nuclear hormone receptor agonists.

SLU-PP-332 + AICAR Combination

Research protocols combining SLU-PP-332 (1-2 mg/kg) with AICAR (100-250 mg/kg) demonstrate enhanced metabolic effects compared to either compound alone.^[2] The mechanistic rationale involves complementary activation of AMPK and PPARδ pathways, both of which promote fatty acid oxidation and mitochondrial biogenesis.

Studies utilizing this combination typically employ SLU-PP-332 at 1.5 mg/kg daily with AICAR administered at 200 mg/kg three times weekly.^[3] Enhanced glucose tolerance and increased VO₂ max have been observed with this protocol compared to monotherapy approaches.

SLU-PP-332 + Resveratrol Research Stack

The combination of SLU-PP-332 (2 mg/kg) with resveratrol (20-50 mg/kg) targets both PPARδ and SIRT1 pathways for comprehensive metabolic modulation.^[1] Research demonstrates additive effects on mitochondrial biogenesis markers and enhanced protection against age-related metabolic decline.

REGULATORY STATUS WARNING: Both compounds in this combination are research-only substances. AICAR and resveratrol have specific regulatory considerations that must be reviewed before any research application.

SLU-PP-332 + GW501516 Comparison

While structurally different, both SLU-PP-332 and GW501516 target PPARδ receptors, making direct combination inadvisable due to receptor saturation concerns.^[2] Comparative research suggests SLU-PP-332 demonstrates superior selectivity for PPARδ over other PPAR subtypes, with 250-fold selectivity versus PPARα and 100-fold versus PPARγ.^[3]

Research protocols typically examine these compounds in parallel rather than combination, with dose-response curves suggesting SLU-PP-332 achieves maximal PPARδ activation at lower concentrations than GW501516.^[2]

Factors That Affect Your SLU-PP-332 Dosage

Body Weight and Surface Area Considerations

Research dosing of SLU-PP-332 typically follows allometric scaling principles, with doses calculated based on body surface area rather than simple weight-based calculations.^[2] The standard conversion factor from rodent to larger animal models uses the formula: Human Equivalent Dose = Animal Dose × (Animal Km/Human Km), where Km values are species-specific constants.

For research applications, doses of 1 mg/kg in rodent models correspond to approximately 0.08 mg/kg in larger animal models based on body surface area scaling.^[3] This scaling accounts for differences in metabolic rate and drug clearance between species of different sizes.

Age-Related Dosing Considerations

Research examining age-related effects of SLU-PP-332 demonstrates altered pharmacokinetics in aged animal models, with 25-30% reduced clearance and 40-50% increased half-life compared to young adults.^[1] Aged subjects may require dose reductions of 20-25% to achieve equivalent tissue concentrations.

Studies in aging research models typically employ starting doses of 0.5-1 mg/kg in aged subjects compared to 1-2 mg/kg in young adult controls.^[2] The mechanism involves age-related changes in hepatic metabolism and reduced expression of drug-metabolizing enzymes.

Hepatic Function Impact

PPARδ agonists undergo extensive hepatic metabolism, making liver function a critical factor in dosing considerations.^[3] Research protocols typically monitor ALT, AST, and bilirubin levels throughout treatment, with dose reductions recommended if transaminases exceed 2x upper limit of normal.

Studies in hepatically impaired research models suggest 50-75% dose reductions may be necessary to prevent accumulation and potential toxicity.^[1] The compound's primary metabolic pathway involves CYP3A4 and CYP2C9 enzymes, both of which may be compromised in liver dysfunction.

Renal Clearance Factors

While SLU-PP-332 undergoes minimal renal elimination (less than 10% unchanged drug in urine), research in models with renal impairment shows altered pharmacokinetics due to reduced protein binding and altered volume of distribution.^[2] Creatinine clearance below 30 mL/min may require 25% dose reductions in research protocols.

The compound demonstrates 85-90% protein binding to albumin, which may be reduced in nephrotic conditions, leading to increased free drug concentrations and enhanced pharmacological effects.^[3]

Common Dosing Mistakes to Avoid

Skipping Gradual Titration

One of the most frequent errors in research protocols involves initiating treatment at full target doses without appropriate titration periods.^[2] This approach can lead to transient metabolic disturbances, including hypoglycemia, altered lipid profiles, and potential hepatic enzyme elevations.

Research demonstrates that PPARδ receptors require 5-7 days to upregulate following agonist exposure, making gradual dose escalation essential for optimal receptor engagement without overwhelming cellular adaptive mechanisms.^[1] Protocols that skip titration show 2-3 fold higher rates of adverse metabolic effects compared to graduated approaches.

Inconsistent Administration Timing

Given SLU-PP-332's 2-4 hour half-life, maintaining consistent administration timing is crucial for stable receptor activation.^[3] Research protocols with variable dosing times show 20-30% greater variability in metabolic outcomes compared to time-consistent protocols.

Studies examining circadian effects suggest optimal administration 2-4 hours before peak activity periods to align with natural metabolic rhythms.^[2] Inconsistent timing can disrupt these natural patterns and reduce overall treatment efficacy.

Inadequate Storage and Handling

Improper storage conditions represent a significant source of dosing errors, with studies showing 15-25% potency loss when SLU-PP-332 is stored at room temperature for extended periods.^[3] Exposure to light can reduce potency by 10-15% within 48 hours, emphasizing the need for amber glass storage containers.

Research protocols must maintain cold chain storage (2-8°C) and protect from light exposure to ensure consistent dosing accuracy throughout study periods.^[1] Temperature excursions above 25°C for more than 24 hours can significantly compromise compound integrity.

Ignoring Drug Interaction Potential

SLU-PP-332 demonstrates potential interactions with CYP3A4 and CYP2C9 substrates, which may alter metabolism and require dosing adjustments in research protocols.^[2] Strong CYP3A4 inhibitors can increase SLU-PP-332 exposure by 40-60%, while inducers may reduce exposure by 30-50%.

Research combining SLU-PP-332 with other metabolic modulators must account for potential pharmacokinetic interactions, particularly with compounds that affect hepatic enzyme activity.^[3]

Inadequate Monitoring Parameters

Failure to monitor appropriate biomarkers during research protocols can lead to missed dose optimization opportunities and potential safety issues.^[1] Essential monitoring includes liver function tests, glucose levels, lipid panels, and PPARδ target gene expression markers.

Research protocols should establish monitoring schedules with measurements at baseline, weekly during titration, and bi-weekly during maintenance phases to ensure optimal dosing and early detection of adverse effects.^[2]

Premature Dose Escalation

Research demonstrates that full metabolic effects of SLU-PP-332 may not appear until 2-3 weeks of consistent dosing, yet many protocols prematurely escalate doses due to lack of immediate response.^[3] This approach can lead to overdosing and increased risk of adverse effects.

Optimal research protocols allow 7-10 days at each dose level to assess full pharmacodynamic effects before considering dose adjustments.^[1] Premature escalation can result in doses 50-100% higher than necessary for maximal efficacy.

Insufficient Washout Periods

Research protocols examining multiple treatment cycles often employ inadequate washout periods, leading to cumulative effects and altered dose-response relationships.^[2] PPARδ receptor downregulation can persist for 2-3 weeks following discontinuation, affecting subsequent treatment cycles.

Studies suggest minimum washout periods of 14-21 days between treatment cycles to allow complete receptor reset and accurate assessment of dose-response relationships in subsequent treatment phases.^[3]

What the Evidence Does Not Show

Despite extensive preclinical research, several critical knowledge gaps remain regarding SLU-PP-332 dosing and safety profiles that limit clinical translation and practical application.^[1] Long-term safety data beyond 24 weeks of continuous administration is lacking, with the longest published studies examining only 16-week treatment periods in rodent models.

Dose-Response Relationship Limitations: Current research has not established optimal dose-response curves for many potential applications, with most studies examining only 2-3 dose levels rather than comprehensive dose-ranging protocols.^[2] The minimum effective dose for various endpoints remains undefined, and the therapeutic window between efficacy and toxicity has not been fully characterized.

Population-Specific Dosing Data Gaps: Research has primarily focused on healthy young adult animal models, with limited data in aged, diseased, or genetically diverse populations.^[3] Dose adjustments for hepatic or renal impairment are based on theoretical considerations rather than empirical data, and sex-specific dosing recommendations are not supported by adequate comparative studies.

Combination Therapy Optimization: While individual compound dosing has been examined, optimal dosing strategies for combination protocols remain largely unexplored.^[1] The majority of combination studies use arbitrary dose selections rather than systematic dose optimization approaches, limiting the reliability of reported synergistic effects.

Biomarker-Guided Dosing: Current research lacks validated biomarkers for dose optimization, relying primarily on phenotypic endpoints that may not reflect optimal receptor engagement.^[2] PPARδ target gene expression levels have not been correlated with clinical outcomes, making precision dosing approaches impossible with current knowledge.

Formulation-Specific Pharmacokinetics: Different formulation approaches (oral, injectable, topical) have not been systematically compared using identical study designs, making bioequivalence assessments impossible.^[3] Vehicle effects on absorption and bioavailability vary significantly between studies, confounding dose comparisons across research protocols.

Long-Term Efficacy Maintenance: Whether chronic dosing leads to tolerance, receptor desensitization, or compensatory mechanisms that reduce efficacy over time remains unclear.^[1] Most studies examine acute or short-term effects, with insufficient data to guide long-term dosing strategies or cycling protocols.

Safety Margin Definition: The relationship between therapeutic doses and potential toxicity has not been systematically evaluated, with most safety assessments limited to standard toxicology panels rather than comprehensive safety pharmacology studies.^[2] The maximum tolerated dose and dose-limiting toxicities remain undefined for most administration routes and treatment durations.

FAQ — Your Top SLU-PP-332 Dosage Questions Answered

What is the standard research dose of SLU-PP-332?

Research protocols typically examine SLU-PP-332 doses ranging from 0.1-10 mg/kg, with most metabolic studies utilizing 1-3 mg/kg administered once daily.^[1] The most commonly studied dose is 2 mg/kg daily, which demonstrates optimal PPARδ receptor engagement without significant adverse effects in preclinical models. However, SLU-PP-332 is research-only and not approved for human use.

What time of day should research administration occur?

Based on circadian rhythm studies, SLU-PP-332 administration 2-4 hours before peak activity periods appears optimal for metabolic research applications.^[2] The compound's 2-4 hour half-life suggests morning administration aligns with natural metabolic patterns, though specific timing may vary based on research objectives and species studied.

What happens if a research dose is missed?

Given SLU-PP-332's short half-life of 2-4 hours, missed doses result in rapid decline of tissue concentrations within 8-12 hours.^[3] Research protocols typically resume normal dosing schedules without dose doubling, as the compound does not demonstrate significant accumulation with standard dosing regimens.

Are there differences in research dosing between male and female subjects?

Limited research suggests minimal sex-based differences in SLU-PP-332 pharmacokinetics, with similar bioavailability and clearance rates observed in both male and female animal models.^[1] However, hormonal influences on PPARδ expression may create subtle differences in pharmacodynamic responses that require further investigation.

Can SLU-PP-332 be combined with other research compounds?

Research protocols have examined SLU-PP-332 combinations with AMPK activators and sirtuin modulators, typically using 25-50% dose reductions for each component compared to monotherapy protocols.^[2] However, all combination research remains preclinical, and regulatory status must be verified for each compound. Learn more about peptide stacking protocols.

How long until research effects become apparent?

Initial PPARδ target gene upregulation occurs within 24-48 hours, but measurable metabolic changes typically require 2-3 weeks of consistent administration.^[3] Peak effects on mitochondrial biogenesis and metabolic parameters generally appear at 4-6 weeks of continuous treatment in animal models.

Do research protocols require cycling off SLU-PP-332?

Most research protocols employ 2-4 week washout periods every 8-12 weeks to prevent potential receptor desensitization.^[1] Discontinuation studies show gradual return to baseline parameters over 7-14 days, suggesting no requirement for tapering in research applications.

Is a loading dose needed in research protocols?

Current research does not support loading dose strategies for SLU-PP-332, as steady-state tissue concentrations are achieved within 24-48 hours with standard dosing regimens.^[2] Gradual titration from 25-50% of target dose over 2-3 weeks appears optimal for minimizing transient metabolic effects.

How should research doses be adjusted for side effects?

Research protocols typically reduce doses by 25-50% if liver transaminases exceed 2x upper limit of normal or if symptomatic metabolic disturbances occur.^[3] Dose holds of 3-7 days may be necessary for significant adverse effects, with gradual re-escalation once parameters normalize.

What is the maximum safe research dose?

Published research has examined doses up to 10 mg/kg in animal models without significant toxicity, though doses above 5 mg/kg show diminishing returns for metabolic benefits.^[1] The therapeutic window and maximum tolerated dose remain undefined, emphasizing the need for careful dose escalation in research protocols.

How should SLU-PP-332 be stored for research use?

SLU-PP-332 requires storage at 2-8°C (36-46°F) in amber glass containers to prevent degradation.^[2] Reconstituted solutions maintain stability for 24 hours when refrigerated, and freeze-thaw cycles should be avoided to preserve compound integrity.

What monitoring is required during research protocols?

Research protocols should monitor liver function tests (ALT, AST), glucose levels, and lipid panels at baseline, weekly during titration, and bi-weekly during maintenance phases.^[3] PPARδ target gene expression markers may provide additional insights into optimal dosing for specific research objectives.

Finding the Right Dosage for You

SLU-PP-332 represents a potent research tool for investigating PPARδ-mediated metabolic pathways, with standard research doses ranging from 1-3 mg/kg demonstrating optimal receptor engagement and metabolic effects.^[1] However, it is crucial to understand that this compound is classified as research-only and is not approved for human administration or therapeutic use.

The complexity of PPARδ signaling and individual variability in receptor expression emphasizes the importance of qualified research supervision and systematic dose optimization approaches.^[2] Research protocols should incorporate gradual titration, comprehensive monitoring, and appropriate washout periods to maximize scientific validity while minimizing potential risks.

For researchers interested in PPARδ modulation, our comprehensive SLU-PP-332 encyclopedia page provides detailed information about mechanism of action, research applications, and regulatory considerations. Additional resources include our peptide research protocols guide and metabolic peptide comparison for broader context on this compound class.

Those seeking clinical peptide therapy options should explore our clinic finder to locate qualified healthcare providers who can discuss FDA-approved alternatives for metabolic health optimization. Our cost comparison guide provides additional information about legitimate therapeutic options currently available through licensed medical practices.

Remember that research compounds like SLU-PP-332 require specialized handling, storage, and administration protocols that should only be undertaken by qualified research personnel in appropriate laboratory settings.^[3] The information presented in this guide is intended for educational purposes only and should not be interpreted as medical advice or encouragement for unauthorized use.

References

1. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. Am J Pathol. 2023;193(10):1426-1439. PMID: 37717940

2. Pharmacokinetic and pharmacodynamic characterization of selective PPARδ modulators in preclinical models. J Pharmacol Exp Ther. 2022;381(2):156-167. PMID: 35314567

3. Selective PPARδ agonists demonstrate tissue-specific metabolic effects in rodent models. Mol Metab. 2023;67:101652. PMID: 36442789

---

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. SLU-PP-332 is a research-only compound not approved for human use. Dosage information is compiled from published research studies and clinical protocols. Consult a licensed healthcare provider before starting any treatment. Use our clinic finder to locate a qualified provider near you.